Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted therapy to improve survival in a molecularly unselected population, and represents a valuable new treatment option. This review describes the current treatment landscape for advanced disease, evaluates existing and ongoing research into ramucirumab, and discusses its current and potential future therapeutic role.
CITATION STYLE
Davidson, M., Smyth, E. C., & Cunningham, D. (2016, July 25). Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma. OncoTargets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/OTT.S84153
Mendeley helps you to discover research relevant for your work.